Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. (NASDAQ: MRNA) is a cutting-edge biotech company based in Cambridge, Massachusetts, founded in 2010. Moderna is at the forefront of pioneering messenger RNA therapeutics™, a revolutionary class of drugs that utilize mRNA technology to direct cells to produce proteins that can fight diseases. This innovative approach has shown promise in addressing targets that were previously considered untreatable with traditional drugs.
With over 200 patent applications and more than 10,000 claims, Moderna has a robust intellectual property portfolio that includes novel nucleotide chemistries and specific drug compositions. The company has successfully developed and commercialized several mRNA-based drugs, initially focusing on rare diseases and oncology, while partnering to advance drug candidates in other therapeutic areas.
Moderna’s mRNA technology gained global recognition with its COVID-19 vaccine, Spikevax®, which was one of the earliest vaccines to receive emergency use authorization in the United States in December 2020. As of mid-2023, Moderna had 39 mRNA development candidates in clinical trials, covering a wide range of therapeutic areas such as infectious diseases, oncology, cardiovascular diseases, and rare genetic disorders.
Some of Moderna's recent achievements include the advancement of three new vaccine programs—targeting Epstein-Barr virus, Varicella-Zoster virus, and norovirus—towards Phase 3 clinical trials. Additionally, the company initiated three new clinical studies combining its investigational individualized neoantigen therapy with Merck’s Keytruda® for treating various cancers.
Financially, Moderna reported first-quarter revenues of $167 million in 2024, with a GAAP net loss of $1.2 billion. Despite the decline in COVID-19 vaccine sales, the company reaffirms its 2024 expected product sales of approximately $4 billion. Moderna is preparing for the launches of its RSV vaccine and the Spikevax® 2024-2025 formula, demonstrating its commitment to fighting respiratory illnesses.
Moderna continues to focus on innovation and operational efficiency, utilizing AI technologies to enhance productivity. The company's long-term vision includes leveraging its mRNA platform to develop therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases, striving to make a significant impact on global health.
Moderna, Inc. (NASDAQ: MRNA) announced a recommendation from the CDC's ACIP for the use of a booster dose of its COVID-19 vaccine at a 50 µg level for individuals aged 65 and older and those aged 18-64 at high risk. This follows FDA's Emergency Use Authorization for the booster. The ACIP's unanimous vote of 15 members emphasizes the need for additional protection against COVID-19. Moderna estimates that this could lead to up to 1 billion additional doses available for distribution in 2022, enhancing its vaccine supply amid ongoing pandemic challenges.
Moderna announced the FDA's Emergency Use Authorization (EUA) for its COVID-19 vaccine booster dose (mRNA-1273) at a 50 µg level. The EUA is for individuals aged 65 and older, and at-risk individuals aged 18 to 64, with administration recommended at least six months post-primary vaccination. The authorization also allows a booster for those previously vaccinated with other COVID-19 vaccines. The decision is based on strong clinical evidence indicating effective immune response post-booster, with unanimous support from the FDA's advisory committee.
Moderna announced a positive, unanimous vote from the FDA's VRBPAC to recommend Emergency Use Authorization for a 50 µg booster dose of its COVID-19 vaccine (mRNA-1273) for individuals aged 65 and older and high-risk adults aged 18 to 64. This vote may enable up to 1 billion additional doses in 2022. The recommendation was based on strong clinical data demonstrating higher antibody responses against COVID-19 variants. The FDA will consider this recommendation for final authorization, followed by a CDC review.
Moderna, Inc. (NASDAQ: MRNA) will host a live conference call and webcast on November 4, 2021, at 8:00 a.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Interested parties can participate by calling 866-922-5184 (domestic) or 409-937-8950 (international) with conference ID 9177025. A webcast will be available on the Moderna Investors website and archived for a year. Moderna has rapidly advanced its mRNA therapeutics, particularly in COVID-19 vaccines, showcasing significant growth in the biotech field.
Moderna announced a significant agreement with COVAX to supply an additional 176.5 million doses of its COVID-19 vaccine. The doses are priced at an average of less than $10 per 100 µg dose, aligning with Moderna's global access principles. Additionally, the company has requested regulatory authorization for a 50 µg booster dose, which could enhance supply for low-income countries. COVAX has already secured over 210 million doses, with options for further purchases. This partnership aims to promote equitable vaccine access worldwide.
Moderna (NASDAQ: MRNA) is set to invest up to $500 million in building a state-of-the-art mRNA manufacturing facility in Africa. This facility aims to produce up to 500 million vaccine doses annually. The investment reflects Moderna's commitment to expanding its global manufacturing capacity and enhancing its mRNA platform, which has been pivotal in COVID-19 vaccine production. The company plans to begin the site selection process soon. Moderna has delivered over 500 million doses of its COVID-19 vaccine globally to date.
Moderna (NASDAQ: MRNA) has launched the Moderna Fellowship Program aimed at fostering a new generation of leaders in mRNA therapeutics and vaccine research. The initiative will select approximately 50 global fellows in its first year, focusing on infectious diseases. Dr. Greg Poland, an expert in infectious diseases, will chair the program. This effort underscores Moderna's commitment to supporting independent research and advancing mRNA-based innovations to improve patient care and population health.
Moderna, Inc. (NASDAQ: MRNA) announced that the European Medicines Agency has authorized a third dose of its COVID-19 vaccine, Spikevax, for severely immunocompromised individuals aged 12 years and older, to be administered at least 28 days after the second dose. Recent studies indicate that a third dose may enhance immune response in this vulnerable population. Moderna reaffirms its commitment to combatting COVID-19 through its mRNA technology, which has yielded effective vaccines and therapeutics.
Moderna, Inc. (NASDAQ: MRNA) has announced plans to invest in a new 462,000 sq. ft. science center in
Moderna (Nasdaq: MRNA) announced that President Stephen Hoge, M.D., will join a fireside chat at Chardan’s Virtual 5th Annual Genetic Medicines Conference on October 5 at 1:00 p.m. ET. Investors can access a live webcast of the event on Moderna's website under “Events and Presentations.” The discussion will be archived for 30 days post-event. Moderna has evolved significantly in its 10 years, focusing on mRNA therapeutics and vaccines, including COVID-19, and has built a diverse clinical portfolio alongside robust manufacturing capabilities.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
What is Moderna’s core business?
What are some recent achievements of Moderna?
How did Moderna gain global recognition?
What is Moderna’s financial outlook for 2024?
What is the significance of Moderna’s mRNA technology?
Where is Moderna headquartered?
How many mRNA development candidates does Moderna have?
What areas does Moderna’s mRNA platform cover?
How is Moderna enhancing its operations?
What is Moderna’s approach to partnerships?
